Used in targeted cancer therapy, particularly for ovarian and non-small cell lung cancers expressing folate receptor alpha (FOLR1). Binds specifically to FOLR1 on cancer cells, enabling immune-mediated destruction through mechanisms like antibody-dependent cellular cytotoxicity (ADCC). Investigated in clinical trials to enhance efficacy of chemotherapy and as a component of antibody-drug conjugates (ADCs) for precise delivery of cytotoxic agents to tumor cells while sparing healthy tissues. Shows potential in diagnostic imaging when labeled with radiotracers to identify FOLR1-positive tumors.